HUTCHMED (HCM) AI Stock Analysis

• Market Cap: $2.08B
• Dividend Yield: N/A
• Average Volume (3M): 48.41K
• Price to Earnings (P/E): 50.1
• Beta (1Y): 0.38
• Revenue Growth: -12.78%
• EPS Growth: 1119.53%
• Country: US
• Employees: 1,811
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.77
• Shares Outstanding: 174,467,030
• 10 Day Avg. Volume: 34,563
• 30 Day Avg. Volume: 48,412
• PEG Ratio: <0.01
• Price to Book (P/B): 1.85
• Price to Sales (P/S): 4.16
• P/FCF Ratio: -28.96
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 3.29
• Enterprise Value/Gross Profit: 36.82
• Enterprise Value/Ebitda: -264.26
• 1Y Price Target: $16.80
• Price Target Upside: 6.73% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 0.32
• Revenue Forecast (FY): $639.86M

• Rating: 53 Neutral
• Price Target: $11.50 ▼(-26.94% Downside)
• Action: Reiterated
• Date: 03/07/26

Positive Factors

Conservative leverage

Very low debt-to-equity (~0.08) and a high balance sheet score indicate durable financial flexibility. This reduces refinancing and interest risk, supports funding of R&D or commercialization in 2–6 months, and allows opportunistic investment or partnership financing without solvency strain.

Negative Factors

Weak operating cash flow

Material negative operating and free cash flow signal the business is consuming cash despite reported earnings. Over 2–6 months this constrains the firm's ability to self-fund trials or commercialization, increasing reliance on external financing or partner milestone timing.

HUTCHMED Business Overview & Revenue Model

Company Description

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The c...

Read more

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The c...

How the Company Makes Money

HUTCHMED generates revenue primarily from (1) product sales of its commercial-stage medicines, where it records net sales from medicines it markets and distributes in its commercial territories; (2) collaboration and licensing arrangements with ph...

Read more

HUTCHMED generates revenue primarily from (1) product sales of its commercial-stage medicines, where it records net sales from medicines it markets and distributes in its commercial territories; (2) collaboration and licensing arrangements with ph...

HUTCHMED Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	602.20M	549.96M	630.20M	838.00M	426.41M	356.13M
Gross Profit	53.76M	212.72M	281.32M	453.55M	115.31M	97.89M
EBITDA	-7.49M	-41.38M	-31.36M	26.58M	-401.11M	-207.96M
Net Income	466.88M	458.12M	37.73M	100.78M	-360.83M	-194.65M
Balance Sheet
Total Assets	1.78B	1.75B	1.27B	1.28B	1.03B	1.37B
Cash, Cash Equivalents and Short-Term Investments	1.36B	1.37B	836.11M	886.34M	631.00M	1.01B
Total Debt	100.73M	97.89M	89.82M	86.13M	27.01M	38.98M
Total Liabilities	534.02M	501.84M	502.34M	536.39M	392.57M	333.15M
Stockholders Equity	1.23B	1.24B	759.93M	730.54M	610.37M	986.89M
Cash Flow
Free Cash Flow	-49.66M	-79.01M	-17.44M	186.65M	-305.26M	-220.98M
Operating Cash Flow	-32.56M	-64.83M	497.00K	219.26M	-268.60M	-204.22M
Investing Cash Flow	-73.03M	-29.49M	-96.06M	-291.14M	296.59M	-306.32M
Financing Cash Flow	11.22M	7.86M	-30.67M	48.66M	-82.76M	650.03M

HUTCHMED Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 15.74
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HCM, the sentiment is Negative. The current price of 15.74 is above the 20-day moving average (MA) of 12.56, above the 50-day MA of 13.79, and above the 200-day MA of 14.69, indicating a bearish trend. The MACD of -0.67 indicates Positive momentum. The RSI at 19.61 is Positive, neither overbought nor oversold. The STOCH value of 13.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HCM.

HUTCHMED Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANIP	76 Outperform	$1.86B	18.92	17.32%	―	37.03%	―
SUPN	63 Neutral	$2.71B	-93.08	-2.73%	―	16.29%	-145.12%
AMRX	60 Neutral	$4.08B	34.81	-144.72%	―	7.62%	―
HCM	53 Neutral	$2.08B	50.09	37.04%	―	-12.78%	1119.53%
PRGO	52 Neutral	$1.54B	-0.87	-50.65%	8.48%	-3.62%	-932.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALVO	44 Neutral	$1.07B	-14.03	35.22%	―	-4.47%	-178.26%